BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia

Reuters2025-04-24

April 24 (Reuters) - Nexalin Technology Inc NXL.O:

NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIA

Source text: ID:nGNEh93

Further company coverage: NXL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2529980998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-24 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529980998","market":"us","top_or_hot":-1,"title":"BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia</title></head><body><p><span>April 24 (Reuters)</span><span> - </span>Nexalin Technology Inc <span>NXL.O</span>:</p><ul><li><p>NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND  BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIA</p></li></ul><p>Source text: <span>ID:nGNEh93</span></p><p>Further company coverage: <span>NXL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-24 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia</title></head><body><p><span>April 24 (Reuters)</span><span> - </span>Nexalin Technology Inc <span>NXL.O</span>:</p><ul><li><p>NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND  BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIA</p></li></ul><p>Source text: <span>ID:nGNEh93</span></p><p>Further company coverage: <span>NXL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NXL","symbol_name":"Nexalin Technology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R236I:1","article_id":"2529980998","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529980998","pubTimestamp":1745499909,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And InsomniaApril 24  - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND  BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIASource text: ID:nGNEh93Further company coverage: NXL.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NXL":"Nexalin Technology, Inc.","BK4082":"医疗保健设备"},"translate_title":"BRIEF-Nexalin技术在巴西获得IRB批准并开始治疗焦虑和失眠的临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXL":0.9},"content_text":"BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And InsomniaApril 24 (Reuters) - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND  BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIASource text: ID:nGNEh93Further company coverage: NXL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529980998","isCrawlerRequest":true}